1. Gilbertson D, Ishani A, Kasiske BL, Liu J. Excerpts From the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis. 2011;55(Suppl 1):2010-1. doi: 10.1053/j.ajkd.2009.10.009
2. Herzog CA. How to manage the renal patient with coronary heart disease: The agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol. 2003;14(10):2556-72. doi: 10.2308/ajpt-50738
3. Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int. 2004;65(6):2380-9. doi: 10.1111/j.1523-1755.2004.00657.x
4. Respalacios FECT, Aylor ALJT, Godoa LAYA, et al. Incident acute coronary syndromes in chronic dialysis patients in the United States 1. Kidney Int. 2002;62:1799-805. doi: 10.1046/j.1523-1755.2002.00638.x
5. Parekh RS, Zhang L, Fivush BA, Klag MJ. Incidence of Atherosclerosis by Race in the Dialysis Morbidity and Mortality Study: A Sample of the US ESRD Population. J Am Soc Nephrol. 2005:1420-6. doi: 10.1681/ASN.2004080661
6. Young BA, Rudser K, Kestenbaum B, Seliger SL, Andress D, Boyko EJ. Racial and ethnic differences in incident myocardial infarction in end-stage renal disease patients: The USRDS. Kidney Int. 2006;69(9):1691-8. doi: 10.1038/sj.ki.5000346
7. Conlon PJ, Krucoff MW, Minda S, Schumm D, Schwab SJ. Incidence and long-term significance of transient ST segment deviation in hemodialysis patients. Clin Nephrol. 1998;49(4):236-9.
8. Go AS, Bansal NMC. Chronic Kidney Disease and Risk of Presenting with Acute Myocardial Infarction versus Stable Exertional Angina in Adults with Coronary Heart Disease. NeuroImage. 2011;85(01):1-27. doi: 10.1016/j.neuroimage.2013.08.045
9. Herzog CA, Littrell K, Arko C, Frederick PD, Blaney M. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: A collaborative project of the United States renal data system and the national registry of myocardial infarction. Circulation. 2007;116(13):1465-72. doi: 10.1161/CIRCULATIONAHA.107.696765
10. Shroff GR, Frederick PD, Herzog CA. Renal failure and acute myocardial infarction: Clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J. 2012;163(3):399-406. doi: 10.1016/j.ahj.2011.12.002
11. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: A report from the national cardiovascular data acute coronary. Circulation. 2010;121(3):357-65. doi: 10.1161/CIRCULATIONAHA.109.865352
12. Szummer K, Lundman P, Jacobson SH, et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: Data from the SWEDEHEART register. J Intern Med. 2010;268(1):40-9. doi: 10.1111/j.1365-2796.2009.02204.x
13. Surana SP, Riella LV, Keithi-Reddy SR, Charytan DM, Singh AK. Acute coronary syndrome in ESRD patients. Kidney Int. 2009;75(5):558-62. doi: 10.1038/ki.2008.233
14. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;1. doi: 10.1016/j.gheart.2018.08.004
15. Dubin RF, Li Y, He J, et al. Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: A cross-sectional study in the chronic renal insufficiency cohort (CRIC). BMC Nephrol. 2013;14(1). doi: 10.1186/1471-2369-14-229
16. Van der Linden N, Cornelis T, Kimenai DM, et al. Origin of Cardiac Troponin T Elevations in Chronic Kidney Disease. Circulation. 2017;136(11):1073-5. doi: 10.1161/CIRCULATIONAHA.117.029986
17. Stacy SR, Suarez-Cuervo C, Berger Z, et al. Role of troponin in patients with chronic kidney disease and suspected acute coronary syndrome: A systematic review. Ann Intern Med. 2014;161(7):502-12. doi: 10.7326/M14-0746
18. Twerenbold R, Wildi K, Jaeger C, et al. Optimal cutoff levels of more sensitive cardiac troponin assays for the early diagnosis of myocardial infarction in patients with renal dysfunction. Circulation. 2015;131(23):2041-50. doi: 10.1161/CIRCULATIONAHA.114.014245
19. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of. Eur Heart J. 2016;37(3):267-315. doi: 10.1093/eurheartj/ehv320
20. Miller-Hodges E, Anand A, Shah ASV, et al. High-Sensitivity Cardiac Troponin and the Risk Stratification of Patients with Renal Impairment Presenting with Suspected Acute Coronary Syndrome. Circulation. 2018;137(5):425-35. doi: 10.1161/CIRCULATIONAHA.117.030320
21. Twerenbold R, Badertscher P, Boeddinghaus J, et al. 0/1-Hour Triage Algorithm for Myocardial Infarction in Patients with Renal Dysfunction. Circulation. 2018;137(5):436-51. doi: 10.1161/CIRCULATIONAHA.117.028901
22. Martin GS, Becker BN, Schulman G. Cardiac troponin-I accurately predicts myocardial injury in renal failure. Nephrol Dial Transplant. 1998;13(7):1709-12. http://www.ncbi.nlm.nih.gov/pubmed/9681716
23. Newby LK, Jesse RL, Babb JD, et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2012;60(23):2427-63. doi: 10.1016/j.jacc.2012.08.969
24. Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation. 2002;106(23):2941-45. http://www.ncbi.nlm.nih.gov/pubmed/12460876
25. Morrow DA, Bonaca MP. Real-world application of “delta” troponin: Diagnostic and prognostic implications. J Am Coll Cardiol. 2013;62(14):1239-41. doi: 10.1016/j.jacc.2013.06.049
26. Bjurman C, Larsson M, Johanson P, et al. Small changes in troponin T levels are common in patients with non-ST-segment elevation myocardial infarction and are linked to higher mortality. J Am Coll Cardiol. 2013;62(14):1231-8. doi: 10.1016/j.jacc.2013.06.050
27. Tun A, Khan IA, Win MT, et al. Specificity of cardiac troponin I and creatine kinase-MB isoenzyme in asymptomatic long-term hemodialysis patients and effect of hemodialysis on these cardiac markers. Cardiology. 1998;90(4):280-5. doi: 10.1159/000006859
28. Lippi G, Tessitore N, Montagnana M, Salvagno GL, Lupo A, Guidi GC. Influence of sampling time and ultrafiltration coefficient of the dialysis membrane on cardiac troponin I and T. Arch Pathol Lab Med. 2008;132(1):72-6. doi: 10.1043/1543-2165(2008)132[72:IOSTAU]2.0.CO;2
29. Wayand D, Baum H, Schatzle G, Scharf J, Neumeier D. Cardiac troponin T and I in end-stage renal failure. Clin Chem. 2000;46(9):1345-50. 
30. Nevis IF, Mathew A, Novick RJ, et al. Optimal method of coronary revascularization in patients receiving dialysis: Systematic review. Clin J Am Soc Nephrol. 2009;4(2):369-78. doi: 10.2215/CJN.02640608
31. Wang Y, Zhu S, Gao P, Zhang Q. Comparison of coronary artery bypass grafting and drug-eluting stents in patients with chronic kidney disease and multivessel disease: A meta-analysis. Eur J Intern Med. 2017;43(2016):28-35. doi: 10.1016/j.ejim.2017.04.002
32. Möckel M, Searle J, Baberg HT, et al. Revascularisation of patients with end-stage renal disease on chronic haemodialysis: bypass surgery versus PCI-analysis of routine statutory health insurance data. Open Hear. 2016;3(2):e000464. doi: 10.1136/openhrt-2016-000464
33. Krishnaswami A, McCulloch CE, Tawadrous M, et al. Coronary artery bypass grafting and percutaneous coronary intervention in patients with end-stage renal disease. Eur J Cardio-thoracic Surg. 2015;47(5):e193-e198. doi: 10.1093/ejcts/ezv104
34. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Revascularization in Patients With Multivessel Coronary Artery Disease and Chronic Kidney Disease: Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery. J Am Coll Cardiol. 2015;66(11):1209-20. doi: 10.1016/j.jacc.2015.06.1334
35. Shroff GR, Solid CA, Herzog CA. Long-term survival and repeat coronary revascularization in dialysis patients after surgical and percutaneous coronary revascularization with drug-eluting and bare metal stents in the united states. Circulation. 2013;127(18):1861-9. doi: 10.1161/CIRCULATIONAHA.112.001264
36. Hemmelgarn BR, Southern D, Culleton BF, et al. Survival after coronary revascularization among patients with kidney disease. Circulation. 2004;110(14):1890-5. doi: 10.1161/01.CIR.0000143629.55725.D9
37. Chen J-J, Lin L-Y, Yang Y-H, et al. On pump versus off pump coronary artery bypass grafting in patients with end-stage renal disease and coronary artery disease – A nation-wide, propensity score matched database analyses. Int J Cardiol. 2017;227:529-34. doi: 10.1016/j.ijcard.2016.10.108
38. Aoyama T, Ishii H, Toriyama T, et al. Sirolimus-eluting stents vs bare metal stents for coronary intervention in Japanese patients with renal failure on hemodialysis. Circ J. 2008;72(1):56-60.
39. Yachi S, Tanabe K, Tanimoto S, et al. Clinical and Angiographic Outcomes Following Percutaneous Coronary Intervention With Sirolimus-Eluting Stents Versus Bare-Metal Stents in Hemodialysis Patients. Am J Kidney Dis. 2009;54(2):299-306. doi: 10.1053/j.ajkd.2009.01.263
40. Chang TI, Montez-Rath ME, Tsai TT, Hlatky MA, Winkelmayer WC. Drug-Eluting Versus Bare-Metal Stents During PCI in Patients With End-Stage Renal Disease on Dialysis. J Am Coll Cardiol. 2016;67(12):1459-69. doi: 10.1016/j.jacc.2015.10.104
41. Li S, Ye D, Chen G, Xu W. Meta-Analysis of Comparison of Drug-Eluting Stents and Bare-Metal Stents in Patients on Dialysis. Am J Cardiol. 2017;119(8):1186-92. doi: 10.1016/j.amjcard.2016.12.036
42. Kaufman JS, O’Connor TZ, Zhang JH, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol. 2003;14(9):2313-21.
43. Hiremath S, Holden RM, Fergusson D, Zimmerman DL. Antiplatelet medications in hemodialysis patients: a systematic review of bleeding rates. Clin J Am Soc Nephrol. 2009;4(8):1347-55. doi: 10.2215/CJN.00810209
44. Herzog CA. The optimal method of coronary revascularization in dialysis patients: choosing between a rock and a hard place. Int J Artif Organs. 2000;23(4):215-8. http://www.ncbi.nlm.nih.gov/pubmed/ 10832653
45. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(4 Suppl 3):S1-153.
46. Sorrell VL. Diagnostic tools and management strategies for coronary artery disease in patients with end-stage renal disease. Semin Nephrol. 2001;21(1):13-24.
47. Frilling B, Zahn R, Fraiture B, et al. Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. Am J Cardiol. 2002;89(4):450-2.
48. Best PJM, Lennon R, Gersh BJ, et al. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J. 2003;146(2):345-50. doi: 10.1016/S0002-8703(03)00231-X
49. Jeremias A, Bhatt DL, Chew DP, et al. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol. 2002;89(10):1209-11.
50. Khaja A, Garg R, Govindarajan G, Madsen R, Aggarwal K. Percutaneous coronary intervention and the use of glycoprotein IIb/IIIa inhibitors in patients with chronic kidney disease on dialysis: A single center experience. Hemodial Int. 2008;12:S2-S8. doi: 10.1111/j.1542-4758.2008.00316.x
51. Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol. 2003;41(5):718-24.
52. Tsai TT, Maddox TM, Roe MT, et al. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA. 2009;302(22):2458-64. doi: 10.1001/jama.2009.1800
53. Ifudu O, Miles AM, Friedman EA. Hemodialysis immediately after acute myocardial infarction. Nephron. 1996;74(1):104-9. doi: 10.1159/000189287
54. Coritsidis G, Sutariya D, Stern A, et al. Does timing of dialysis in patients with ESRD and acute myocardial infarcts affect morbidity or mortality? Clin J Am Soc Nephrol. 2009;4(8):1324-30. doi: 10.2215/CJN.04470908
55. Chapter 1: Definition and classification of CKD. Kidney Int Suppl. 2013;3(1):19-62. doi: 10.1038/kisup.2012.64
56. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238-48. doi: 10.1056/NEJMoa043545
57. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395-407. doi: 10.1056/NEJMoa0810177
58. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet (London, England). 2011;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3
59. Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157(4):251-62. doi: 10.7326/0003-4819-157-4-201208210-00005
60. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GFM. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157(4):263-75. doi: 10.7326/0003-4819-157-4-201208210-00007
61. Hou W, Lv J, Perkovic V, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J. 2013;34(24):1807-17. doi: 10.1093/eurheartj/eht065
62. Ethier J, Bragg-Gresham JL, Piera L, et al. Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2007;50(4):602-11. doi: 10.1053/j.ajkd.2007.07.007
63. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Anticoagulant and Antiplatelet Usage Associates with Mortality among Hemodialysis Patients. J Am Soc Nephrol. 2009;20(4):872-81. doi: 10.1681/ASN.2008080824
64. Palmer SC, Di Micco L, Razavian M, et al. Antiplatelet agents for chronic kidney disease. Palmer SC, ed. Cochrane Database Syst Rev. 2013;(2):CD008834. doi: 10.1002/14651858.CD008834.pub2
65. Foundation: NK. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney. 2005;45(4):51-3. doi: 10.1053/j.ajkd.2005.01.016
66. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42(2):201-8.
67. Knoll GA, Sahgal A, Nair RC, Graham J, van Walraven C, Burns KD. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med. 2002;112(2):110-4.
68. Miskulin D, Sarnak M. A β-blocker trial in dialysis patients: Is it feasible and worthwhile? Am J Kidney Dis. 2016;67(6):822-5. doi: 10.1053/j.ajkd.2016.03.413
69. Weir MA, Dixon SN, Fleet JL, et al. β-Blocker Dialyzability and Mortality in Older Patients Receiving Hemodialysis. J Am Soc Nephrol. 2015;26(4):987-96. doi: 10.1681/ASN.2014040324
70. Struthers A, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res. 2004;61(4):663-70. doi: 10.1016/j.cardiores.2003.11.037
71. Quach K, Lvtvyn L, Baigent C, et al. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2016;68(4):591-8. doi: 10.1053/j.ajkd.2016.04.011
72. Zhao Y, Yan B, Zhao Z, Wang S, Weng X. Safety and cardiovascular effects of mineralocorticoid receptor antagonists for patients receiving hemodialysis: A systematic review and meta-analysis. Ren Fail. 2016;38(4):589-99. doi: 10.3109/0886022X.2016.1149684
73. Flevari P, Kalogeropoulou S, Drakou A, et al. Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients. J Hypertens. 2013;31(6):1239-44. doi: 10.1097/HJH.0b013e32835f955c
74. Matsumoto Y, Mori Y, Kageyama S, et al. Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients. J Am Coll Cardiol. 2014;63(6):528-36. doi: 10.1016/j.jacc.2013.09.056
75. Hammer F, Krane V, Störk S, et al. Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa). Nephrol Dial Transplant. 2014;29(2):400-5. doi: 10.1093/ndt/gft409
76. Walsh M, Manns B, Garg AX, et al. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial. Clin J Am Soc Nephrol. 2015;10(9):1602-8. doi: 10.2215/CJN.12371214
77. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339(12):799-805. doi: 10.1056/NEJM199809173391203
78. Chertow GM, Normand SL, Silva LR, McNeil BJ. Survival after acute myocardial infarction in patients with end-stage renal disease: results from the cooperative cardiovascular project. Am J Kidney Dis. 2000;35(6):1044-51.
79. Iseki K, Fukiyama K. Long-term prognosis and incidence of acute myocardial infarction in patients on chronic hemodialysis. The Okinawa Dialysis Study Group. Am J Kidney Dis. 2000;36(4):820-5.
80. Baber U, Kini AS, Sharma SK, Kim MC, Farkouh ME, Muntner P. Thrombolysis In Myocardial Infarction (TIMI) risk score and mortality in patients with advanced chronic kidney disease and on dialysis. Am J Cardiol. 2009;103(11):1513-7. doi: 10.1016/j.amjcard.2009.01.364
81. Michos ED, Wilson LM, Yeh H-C, et al. Prognostic value of cardiac troponin in patients with chronic kidney disease without suspected acute coronary syndrome: a systematic review and meta-analysis. Ann Intern Med. 2014;161(7):491-501. doi: 10.7326/M14-0743
82. Hickson LJ, Cosio FG, El-Zoghby ZM, et al. Survival of patients on the kidney transplant wait list: relationship to cardiac troponin T. Am J Transplant. 2008;8(11):2352-9. doi: 10.1111/j.1600-6143.2008.02395.x
83. Havekes B, van Manen JG, Krediet RT, et al. Serum troponin T concentration as a predictor of mortality in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 2006;47(5):823-9. doi: 10.1053/j.ajkd.2006.01.019
84. McGill D, Talaulikar G, Potter JM, Koerbin G, Hickman PE. Over time, high-sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysis-dependent chronic renal failure. Clin Chim Acta. 2010;411(13-14):936-9. doi: 10.1016/j.cca.2010.03.004
85. Hassan HC, Howlin K, Jefferys A, et al. High-Sensitivity Troponin as a Predictor of Cardiac Events and Mortality in the Stable Dialysis Population. Clin Chem. 2014;60(2):389-98. doi: 10.1373/clinchem.2013.207142
86. Lentine KL, Costa SP, Weir MR, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2012;60(5):434-80. doi: 10.1016/j.jacc.2012.05.008

________________________________________________

1. Gilbertson D, Ishani A, Kasiske BL, Liu J. Excerpts From the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis. 2011;55(Suppl 1):2010-1. doi: 10.1053/j.ajkd.2009.10.009
2. Herzog CA. How to manage the renal patient with coronary heart disease: The agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol. 2003;14(10):2556-72. doi: 10.2308/ajpt-50738
3. Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int. 2004;65(6):2380-9. doi: 10.1111/j.1523-1755.2004.00657.x
4. Respalacios FECT, Aylor ALJT, Godoa LAYA, et al. Incident acute coronary syndromes in chronic dialysis patients in the United States 1. Kidney Int. 2002;62:1799-805. doi: 10.1046/j.1523-1755.2002.00638.x
5. Parekh RS, Zhang L, Fivush BA, Klag MJ. Incidence of Atherosclerosis by Race in the Dialysis Morbidity and Mortality Study: A Sample of the US ESRD Population. J Am Soc Nephrol. 2005:1420-6. doi: 10.1681/ASN.2004080661
6. Young BA, Rudser K, Kestenbaum B, Seliger SL, Andress D, Boyko EJ. Racial and ethnic differences in incident myocardial infarction in end-stage renal disease patients: The USRDS. Kidney Int. 2006;69(9):1691-8. doi: 10.1038/sj.ki.5000346
7. Conlon PJ, Krucoff MW, Minda S, Schumm D, Schwab SJ. Incidence and long-term significance of transient ST segment deviation in hemodialysis patients. Clin Nephrol. 1998;49(4):236-9.
8. Go AS, Bansal NMC. Chronic Kidney Disease and Risk of Presenting with Acute Myocardial Infarction versus Stable Exertional Angina in Adults with Coronary Heart Disease. NeuroImage. 2011;85(01):1-27. doi: 10.1016/j.neuroimage.2013.08.045
9. Herzog CA, Littrell K, Arko C, Frederick PD, Blaney M. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: A collaborative project of the United States renal data system and the national registry of myocardial infarction. Circulation. 2007;116(13):1465-72. doi: 10.1161/CIRCULATIONAHA.107.696765
10. Shroff GR, Frederick PD, Herzog CA. Renal failure and acute myocardial infarction: Clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J. 2012;163(3):399-406. doi: 10.1016/j.ahj.2011.12.002
11. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: A report from the national cardiovascular data acute coronary. Circulation. 2010;121(3):357-65. doi: 10.1161/CIRCULATIONAHA.109.865352
12. Szummer K, Lundman P, Jacobson SH, et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: Data from the SWEDEHEART register. J Intern Med. 2010;268(1):40-9. doi: 10.1111/j.1365-2796.2009.02204.x
13. Surana SP, Riella LV, Keithi-Reddy SR, Charytan DM, Singh AK. Acute coronary syndrome in ESRD patients. Kidney Int. 2009;75(5):558-62. doi: 10.1038/ki.2008.233
14. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;1. doi: 10.1016/j.gheart.2018.08.004
15. Dubin RF, Li Y, He J, et al. Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: A cross-sectional study in the chronic renal insufficiency cohort (CRIC). BMC Nephrol. 2013;14(1). doi: 10.1186/1471-2369-14-229
16. Van der Linden N, Cornelis T, Kimenai DM, et al. Origin of Cardiac Troponin T Elevations in Chronic Kidney Disease. Circulation. 2017;136(11):1073-5. doi: 10.1161/CIRCULATIONAHA.117.029986
17. Stacy SR, Suarez-Cuervo C, Berger Z, et al. Role of troponin in patients with chronic kidney disease and suspected acute coronary syndrome: A systematic review. Ann Intern Med. 2014;161(7):502-12. doi: 10.7326/M14-0746
18. Twerenbold R, Wildi K, Jaeger C, et al. Optimal cutoff levels of more sensitive cardiac troponin assays for the early diagnosis of myocardial infarction in patients with renal dysfunction. Circulation. 2015;131(23):2041-50. doi: 10.1161/CIRCULATIONAHA.114.014245
19. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of. Eur Heart J. 2016;37(3):267-315. doi: 10.1093/eurheartj/ehv320
20. Miller-Hodges E, Anand A, Shah ASV, et al. High-Sensitivity Cardiac Troponin and the Risk Stratification of Patients with Renal Impairment Presenting with Suspected Acute Coronary Syndrome. Circulation. 2018;137(5):425-35. doi: 10.1161/CIRCULATIONAHA.117.030320
21. Twerenbold R, Badertscher P, Boeddinghaus J, et al. 0/1-Hour Triage Algorithm for Myocardial Infarction in Patients with Renal Dysfunction. Circulation. 2018;137(5):436-51. doi: 10.1161/CIRCULATIONAHA.117.028901
22. Martin GS, Becker BN, Schulman G. Cardiac troponin-I accurately predicts myocardial injury in renal failure. Nephrol Dial Transplant. 1998;13(7):1709-12. http://www.ncbi.nlm.nih.gov/pubmed/9681716
23. Newby LK, Jesse RL, Babb JD, et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2012;60(23):2427-63. doi: 10.1016/j.jacc.2012.08.969
24. Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation. 2002;106(23):2941-45. http://www.ncbi.nlm.nih.gov/pubmed/12460876
25. Morrow DA, Bonaca MP. Real-world application of “delta” troponin: Diagnostic and prognostic implications. J Am Coll Cardiol. 2013;62(14):1239-41. doi: 10.1016/j.jacc.2013.06.049
26. Bjurman C, Larsson M, Johanson P, et al. Small changes in troponin T levels are common in patients with non-ST-segment elevation myocardial infarction and are linked to higher mortality. J Am Coll Cardiol. 2013;62(14):1231-8. doi: 10.1016/j.jacc.2013.06.050
27. Tun A, Khan IA, Win MT, et al. Specificity of cardiac troponin I and creatine kinase-MB isoenzyme in asymptomatic long-term hemodialysis patients and effect of hemodialysis on these cardiac markers. Cardiology. 1998;90(4):280-5. doi: 10.1159/000006859
28. Lippi G, Tessitore N, Montagnana M, Salvagno GL, Lupo A, Guidi GC. Influence of sampling time and ultrafiltration coefficient of the dialysis membrane on cardiac troponin I and T. Arch Pathol Lab Med. 2008;132(1):72-6. doi: 10.1043/1543-2165(2008)132[72:IOSTAU]2.0.CO;2
29. Wayand D, Baum H, Schatzle G, Scharf J, Neumeier D. Cardiac troponin T and I in end-stage renal failure. Clin Chem. 2000;46(9):1345-50. 
30. Nevis IF, Mathew A, Novick RJ, et al. Optimal method of coronary revascularization in patients receiving dialysis: Systematic review. Clin J Am Soc Nephrol. 2009;4(2):369-78. doi: 10.2215/CJN.02640608
31. Wang Y, Zhu S, Gao P, Zhang Q. Comparison of coronary artery bypass grafting and drug-eluting stents in patients with chronic kidney disease and multivessel disease: A meta-analysis. Eur J Intern Med. 2017;43(2016):28-35. doi: 10.1016/j.ejim.2017.04.002
32. Möckel M, Searle J, Baberg HT, et al. Revascularisation of patients with end-stage renal disease on chronic haemodialysis: bypass surgery versus PCI-analysis of routine statutory health insurance data. Open Hear. 2016;3(2):e000464. doi: 10.1136/openhrt-2016-000464
33. Krishnaswami A, McCulloch CE, Tawadrous M, et al. Coronary artery bypass grafting and percutaneous coronary intervention in patients with end-stage renal disease. Eur J Cardio-thoracic Surg. 2015;47(5):e193-e198. doi: 10.1093/ejcts/ezv104
34. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Revascularization in Patients With Multivessel Coronary Artery Disease and Chronic Kidney Disease: Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery. J Am Coll Cardiol. 2015;66(11):1209-20. doi: 10.1016/j.jacc.2015.06.1334
35. Shroff GR, Solid CA, Herzog CA. Long-term survival and repeat coronary revascularization in dialysis patients after surgical and percutaneous coronary revascularization with drug-eluting and bare metal stents in the united states. Circulation. 2013;127(18):1861-9. doi: 10.1161/CIRCULATIONAHA.112.001264
36. Hemmelgarn BR, Southern D, Culleton BF, et al. Survival after coronary revascularization among patients with kidney disease. Circulation. 2004;110(14):1890-5. doi: 10.1161/01.CIR.0000143629.55725.D9
37. Chen J-J, Lin L-Y, Yang Y-H, et al. On pump versus off pump coronary artery bypass grafting in patients with end-stage renal disease and coronary artery disease – A nation-wide, propensity score matched database analyses. Int J Cardiol. 2017;227:529-34. doi: 10.1016/j.ijcard.2016.10.108
38. Aoyama T, Ishii H, Toriyama T, et al. Sirolimus-eluting stents vs bare metal stents for coronary intervention in Japanese patients with renal failure on hemodialysis. Circ J. 2008;72(1):56-60.
39. Yachi S, Tanabe K, Tanimoto S, et al. Clinical and Angiographic Outcomes Following Percutaneous Coronary Intervention With Sirolimus-Eluting Stents Versus Bare-Metal Stents in Hemodialysis Patients. Am J Kidney Dis. 2009;54(2):299-306. doi: 10.1053/j.ajkd.2009.01.263
40. Chang TI, Montez-Rath ME, Tsai TT, Hlatky MA, Winkelmayer WC. Drug-Eluting Versus Bare-Metal Stents During PCI in Patients With End-Stage Renal Disease on Dialysis. J Am Coll Cardiol. 2016;67(12):1459-69. doi: 10.1016/j.jacc.2015.10.104
41. Li S, Ye D, Chen G, Xu W. Meta-Analysis of Comparison of Drug-Eluting Stents and Bare-Metal Stents in Patients on Dialysis. Am J Cardiol. 2017;119(8):1186-92. doi: 10.1016/j.amjcard.2016.12.036
42. Kaufman JS, O’Connor TZ, Zhang JH, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol. 2003;14(9):2313-21.
43. Hiremath S, Holden RM, Fergusson D, Zimmerman DL. Antiplatelet medications in hemodialysis patients: a systematic review of bleeding rates. Clin J Am Soc Nephrol. 2009;4(8):1347-55. doi: 10.2215/CJN.00810209
44. Herzog CA. The optimal method of coronary revascularization in dialysis patients: choosing between a rock and a hard place. Int J Artif Organs. 2000;23(4):215-8. http://www.ncbi.nlm.nih.gov/pubmed/ 10832653
45. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(4 Suppl 3):S1-153.
46. Sorrell VL. Diagnostic tools and management strategies for coronary artery disease in patients with end-stage renal disease. Semin Nephrol. 2001;21(1):13-24.
47. Frilling B, Zahn R, Fraiture B, et al. Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. Am J Cardiol. 2002;89(4):450-2.
48. Best PJM, Lennon R, Gersh BJ, et al. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J. 2003;146(2):345-50. doi: 10.1016/S0002-8703(03)00231-X
49. Jeremias A, Bhatt DL, Chew DP, et al. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol. 2002;89(10):1209-11.
50. Khaja A, Garg R, Govindarajan G, Madsen R, Aggarwal K. Percutaneous coronary intervention and the use of glycoprotein IIb/IIIa inhibitors in patients with chronic kidney disease on dialysis: A single center experience. Hemodial Int. 2008;12:S2-S8. doi: 10.1111/j.1542-4758.2008.00316.x
51. Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol. 2003;41(5):718-24.
52. Tsai TT, Maddox TM, Roe MT, et al. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA. 2009;302(22):2458-64. doi: 10.1001/jama.2009.1800
53. Ifudu O, Miles AM, Friedman EA. Hemodialysis immediately after acute myocardial infarction. Nephron. 1996;74(1):104-9. doi: 10.1159/000189287
54. Coritsidis G, Sutariya D, Stern A, et al. Does timing of dialysis in patients with ESRD and acute myocardial infarcts affect morbidity or mortality? Clin J Am Soc Nephrol. 2009;4(8):1324-30. doi: 10.2215/CJN.04470908
55. Chapter 1: Definition and classification of CKD. Kidney Int Suppl. 2013;3(1):19-62. doi: 10.1038/kisup.2012.64
56. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238-48. doi: 10.1056/NEJMoa043545
57. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395-407. doi: 10.1056/NEJMoa0810177
58. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet (London, England). 2011;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3
59. Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157(4):251-62. doi: 10.7326/0003-4819-157-4-201208210-00005
60. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GFM. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157(4):263-75. doi: 10.7326/0003-4819-157-4-201208210-00007
61. Hou W, Lv J, Perkovic V, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J. 2013;34(24):1807-17. doi: 10.1093/eurheartj/eht065
62. Ethier J, Bragg-Gresham JL, Piera L, et al. Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2007;50(4):602-11. doi: 10.1053/j.ajkd.2007.07.007
63. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Anticoagulant and Antiplatelet Usage Associates with Mortality among Hemodialysis Patients. J Am Soc Nephrol. 2009;20(4):872-81. doi: 10.1681/ASN.2008080824
64. Palmer SC, Di Micco L, Razavian M, et al. Antiplatelet agents for chronic kidney disease. Palmer SC, ed. Cochrane Database Syst Rev. 2013;(2):CD008834. doi: 10.1002/14651858.CD008834.pub2
65. Foundation: NK. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney. 2005;45(4):51-3. doi: 10.1053/j.ajkd.2005.01.016
66. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42(2):201-8.
67. Knoll GA, Sahgal A, Nair RC, Graham J, van Walraven C, Burns KD. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med. 2002;112(2):110-4.
68. Miskulin D, Sarnak M. A β-blocker trial in dialysis patients: Is it feasible and worthwhile? Am J Kidney Dis. 2016;67(6):822-5. doi: 10.1053/j.ajkd.2016.03.413
69. Weir MA, Dixon SN, Fleet JL, et al. β-Blocker Dialyzability and Mortality in Older Patients Receiving Hemodialysis. J Am Soc Nephrol. 2015;26(4):987-96. doi: 10.1681/ASN.2014040324
70. Struthers A, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res. 2004;61(4):663-70. doi: 10.1016/j.cardiores.2003.11.037
71. Quach K, Lvtvyn L, Baigent C, et al. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2016;68(4):591-8. doi: 10.1053/j.ajkd.2016.04.011
72. Zhao Y, Yan B, Zhao Z, Wang S, Weng X. Safety and cardiovascular effects of mineralocorticoid receptor antagonists for patients receiving hemodialysis: A systematic review and meta-analysis. Ren Fail. 2016;38(4):589-99. doi: 10.3109/0886022X.2016.1149684
73. Flevari P, Kalogeropoulou S, Drakou A, et al. Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients. J Hypertens. 2013;31(6):1239-44. doi: 10.1097/HJH.0b013e32835f955c
74. Matsumoto Y, Mori Y, Kageyama S, et al. Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients. J Am Coll Cardiol. 2014;63(6):528-36. doi: 10.1016/j.jacc.2013.09.056
75. Hammer F, Krane V, Störk S, et al. Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa). Nephrol Dial Transplant. 2014;29(2):400-5. doi: 10.1093/ndt/gft409
76. Walsh M, Manns B, Garg AX, et al. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial. Clin J Am Soc Nephrol. 2015;10(9):1602-8. doi: 10.2215/CJN.12371214
77. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339(12):799-805. doi: 10.1056/NEJM199809173391203
78. Chertow GM, Normand SL, Silva LR, McNeil BJ. Survival after acute myocardial infarction in patients with end-stage renal disease: results from the cooperative cardiovascular project. Am J Kidney Dis. 2000;35(6):1044-51.
79. Iseki K, Fukiyama K. Long-term prognosis and incidence of acute myocardial infarction in patients on chronic hemodialysis. The Okinawa Dialysis Study Group. Am J Kidney Dis. 2000;36(4):820-5.
80. Baber U, Kini AS, Sharma SK, Kim MC, Farkouh ME, Muntner P. Thrombolysis In Myocardial Infarction (TIMI) risk score and mortality in patients with advanced chronic kidney disease and on dialysis. Am J Cardiol. 2009;103(11):1513-7. doi: 10.1016/j.amjcard.2009.01.364
81. Michos ED, Wilson LM, Yeh H-C, et al. Prognostic value of cardiac troponin in patients with chronic kidney disease without suspected acute coronary syndrome: a systematic review and meta-analysis. Ann Intern Med. 2014;161(7):491-501. doi: 10.7326/M14-0743
82. Hickson LJ, Cosio FG, El-Zoghby ZM, et al. Survival of patients on the kidney transplant wait list: relationship to cardiac troponin T. Am J Transplant. 2008;8(11):2352-9. doi: 10.1111/j.1600-6143.2008.02395.x
83. Havekes B, van Manen JG, Krediet RT, et al. Serum troponin T concentration as a predictor of mortality in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 2006;47(5):823-9. doi: 10.1053/j.ajkd.2006.01.019
84. McGill D, Talaulikar G, Potter JM, Koerbin G, Hickman PE. Over time, high-sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysis-dependent chronic renal failure. Clin Chim Acta. 2010;411(13-14):936-9. doi: 10.1016/j.cca.2010.03.004
85. Hassan HC, Howlin K, Jefferys A, et al. High-Sensitivity Troponin as a Predictor of Cardiac Events and Mortality in the Stable Dialysis Population. Clin Chem. 2014;60(2):389-98. doi: 10.1373/clinchem.2013.207142
86. Lentine KL, Costa SP, Weir MR, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2012;60(5):434-80. doi: 10.1016/j.jacc.2012.05.008

Д.Э. Антух1, Д.Ю. Щекочихин1, А.П. Нестеров2, М.Ю. Гиляров2

1 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
2 ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия

________________________________________________

D.E. Antukh1, D.Yu. Shchekochikhin1, A.P. Nesterov2, M.Yu. Gilarov2 

1 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
2 Pirogov Russian National Research Medical University, Moscow, Russia